{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:52:18Z","timestamp":1787673138958,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:p>Better adherence to supportive care guidelines is needed, especially for common challenges such as chemotherapy-induced nausea and vomiting. This commentary remarks on recently published data on adherence to guidelines, considering treatment options and new strategies to reduce chemotherapy complications.<\/jats:p>","DOI":"10.1002\/onco.13681","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T06:37:50Z","timestamp":1611124670000},"page":"274-276","source":"Crossref","is-referenced-by-count":5,"title":["Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future"],"prefix":"10.1093","volume":"26","author":[{"given":"Alfred I.","family":"Neugut","sequence":"first","affiliation":[{"name":"Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Bates","sequence":"additional","affiliation":[{"name":"Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"2021122512040312200_onco13681-bib-0001","article-title":"Avoidable acute care use associated with nausea and vomiting among patients receiving highy emetogenic chemotherapy or oxaliplatin","author":"Navari","year":"2020","journal-title":"The Oncologist"},{"key":"2021122512040312200_onco13681-bib-0002","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JOP.17.00081","article-title":"Best practices for reducing unplanned acute care for patients with cancer","volume":"14","author":"Handley","year":"2018","journal-title":"J Oncol Pract"},{"key":"2021122512040312200_onco13681-bib-0003","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/0-387-31056-8_83","volume-title":"Oncology: An Evidence-Based Approach","author":"Gill","year":"2006"},{"key":"2021122512040312200_onco13681-bib-0004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","article-title":"ASCO, NCCN, MASCC\/ESMO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients","volume":"27","author":"Razvi","year":"2019","journal-title":"Support Care Cancer"},{"key":"2021122512040312200_onco13681-bib-0005","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","article-title":"Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone","volume":"19","author":"Campos","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122512040312200_onco13681-bib-0006","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122512040312200_onco13681-bib-0007","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122512040312200_onco13681-bib-0008","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/JOP.19.00457","article-title":"Impact of addition of carboplatin AUC \u2265\u20094 to antiemetic guidelines for triple antiemetic prophylaxis: A gap in quality of care, guideline adoption, and avoiding acute care","volume":"16","author":"Navari","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2021122512040312200_onco13681-bib-0009","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6004\/jnccn.2019.7526","article-title":"What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy","volume":"18","author":"Roeland","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122512040312200_onco13681-bib-0010","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122512040312200_onco13681-bib-0011","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1007\/s00520-019-04730-3","article-title":"Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy","volume":"27","author":"Mahendraratnam","year":"2019","journal-title":"Support Care Cancer"},{"key":"2021122512040312200_onco13681-bib-0012","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1377\/hlthaff.2014.0280","article-title":"Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer","volume":"33","author":"Brooks","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"2021122512040312200_onco13681-bib-0013","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: Results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122512040312200_onco13681-bib-0014","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults","volume":"9","author":"Sutherland","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122512040312200_onco13681-bib-0015","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1007\/s00520-020-05380-6","article-title":"Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy","volume":"28","author":"Ithimakin","year":"2020","journal-title":"Support Care Cancer"},{"key":"2021122512040312200_onco13681-bib-0016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122512040312200_onco13681-bib-0017","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/CCO.0000000000000450","article-title":"The latest consensus on antiemetics","volume":"30","author":"Herrstedt","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"2021122512040312200_onco13681-bib-0018","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122512040312200_onco13681-bib-0019","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13680","article-title":"Reconsidering dexamethasone for anti-emesis when combining chemotherapy and immunotherapy","author":"Janowitz","year":"2021","journal-title":"The Oncologist"},{"key":"2021122512040312200_onco13681-bib-0020","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/d41573-020-00166-1","article-title":"Immuno-oncology drug development forges on despite COVID-19","volume":"19","author":"Upadhaya","year":"2020","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13681","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/274\/41923270\/oncolo_26_4_274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/274\/41923270\/oncolo_26_4_274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T12:05:11Z","timestamp":1640433911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/4\/274\/6445532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,3,4]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13681","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,3,4]]}}}